What is HEPAprint?



HEPAprint  is a predictive software solution that uses an individual patient's genes to help guide clinicians to make prescribing decisions that are safer for that patient.

It does this by highlighting any mutations that the patient has that would increase their risk of having an adverse drug reaction to a particular drug or biologic agent.

In essense, it is a prescribing decision support tool that helps clinicians risk stratify prescribing at the point-of-prescribing, in real time. It is  focused primarily on predicting idiosyncratic adverse drug reactions as these are the ones that are hardest to predict using other diagnostic markers.

How did the vision for HEPAprint come about?



HEPAprint was conceptualized by Altaf Mamujee, an experienced clinician/pharmacist and strategic health consultant that had always been concerned about the prospect of one of his patients have an unforeseen idiosyncratic adverse reaction to medicines. The concern initially came about when Altaf began prescribing the blood thinning agent warfarin to his patients when he ran anticoagulation clinics in 2008 and 2015. There was no way of effectively predicting which patients were hypersensitive to warfarin when he saw them at their first clinic appointment.

More recently, Altaf has been involved in reviewing the prescribing of anti-retroviral drugs for treating HIV within the East of England. Altaf noticed that patients newly diagnosed with HIV would have to have HLA-genotyping done to check that they were not HLA-B*5701-positive – which would make them hypersensitive to abacavir – a key first-line drug for patients newly diagnosed with HIV. HLA genotyping would mean that the patient would have to be put an alternative (and more expensive) drug to abacavir, pending the results of the test. Altaf recognised that a solution such as HEPAprint would provide a real-time solution to this real-world problem – saving time and money in the process.

Recognising that there was a need to take growing research that links genetic mutations and adverse drug reactions Altaf took his idea to the Genomics – Encoding the Future Venture Creation Weekend, where it was further developed into a successful pitch that won first prize.

HEPAprint graduated from the University of Cambridge Judge Business School Accelerator (Pre-Accelerate Cambridge) in March 2019.

HEPAprint was a Downing Enterprise Finalist for March 2019.